Show simple item record

dc.contributor.authorHatziagorou, Elpisen
dc.contributor.authorKouroukli, Eleanaen
dc.contributor.authorGalogavrou, Mariaen
dc.contributor.authorPapanikolaou, Dafnien
dc.contributor.authorTerzi, Despoinaen
dc.contributor.authorAnagnostopoulou, Pinelopien
dc.contributor.authorKirvassilis, Fotiosen
dc.contributor.authorPanagiotakos, Demosthenes B.en
dc.contributor.authorTsanakas, Johnen
dc.creatorHatziagorou, Elpisen
dc.creatorKouroukli, Eleanaen
dc.creatorGalogavrou, Mariaen
dc.creatorPapanikolaou, Dafnien
dc.creatorTerzi, Despoinaen
dc.creatorAnagnostopoulou, Pinelopien
dc.creatorKirvassilis, Fotiosen
dc.creatorPanagiotakos, Demosthenes B.en
dc.creatorTsanakas, Johnen
dc.description.abstractBackground: Inhaled Corticosteroids (ICS) are the cornerstone of asthma management in pediatric patients. However, in some cases, asthma is not adequately controlled on ICS alone. Long-acting beta2-agonists (LABA) are one of the available additional therapies but their use has rarely been studied among children younger than 5 years. Objective: The aim of this observational study was to evaluate the efficacy and safety of the combination of fluticasone propionate and salmeterol (FP/SA) in asthmatic children younger than 5 years of age. Methods: A retrospective study of 796 children under the age of 5 years (2.87 ± 1.22 years, 64.2% males), who were treated with FP/SA was conducted. Hospitalization rates, frequency of wheezing, exercise induced asthma, nocturnal wheeze and drug-related side-effects were recorded through children's medical records. Results: The children had previously received short-acting β2-agonists (73%), ICS (17%), montelukast (1%), and ICS with montelukast (2%). Mean duration of therapy with FP/SA was 12.45 ± 9.14 months. After adjusting for age, gender, and duration of treatment, a 89% reduction was recorded in annual hospitalization rates (from 27.13% before treatment to 3.01% after FP/SA therapy, p < 0.001), a 71% reduction in incidence of exercise-induced asthma (36.8% vs. after 10.6%, p < 0.001), a 81% reduction in nocturnal asthma (33.7% vs. after: 6.4%, p < 0.001), as well as in frequency of wheezing (p < 0.01),. No previous treatment carry-on effect was observed. No major drug-related side-effects occurred in the study group. Conclusions: Combination therapy (FP/SA) is well-tolerated and highly effective in asthmatic children under the age of 5 years.en
dc.sourceJournal of Asthmaen
dc.titleEfficacy and safety of the combination fluticasone propionate plus salmeterol in asthmatic preschoolers: An observational studyen
dc.description.endingpage580Ιατρική Σχολή / Medical SchoolΙατρική Σχολή / Medical School
dc.contributor.orcidAnagnostopoulou, Pinelopi [0000-0003-2597-8016]
dc.contributor.orcidHatziagorou, Elpis [0000-0001-9505-2054]
dc.contributor.orcidKouroukli, Eleana [0000-0003-2198-3694]
dc.contributor.orcidPanagiotakos, Demosthenes B. [0000-0001-8583-153X]

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record